Samarth Kulkarni Crispr Therapeutics Ag (CRSP) insider trading activity

Samarth Kulkarni is Chief Executive Officer of CRISPR Therapeutics AG. Currently has a direct ownership of 181,540 shares of CRSP, which is worth approximately $7.39 Million. The most recent transaction as insider was on Jul 27, 2022, when has been sold 25,000 shares (Common Shares) at a price of $14.39 per share, resulting in proceeds of $359,750. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 182K

18.41% 3M change

53.14% 12M change

Total Value Held $7.39 Million

Samarth Kulkarni Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 27 2022	BUY Exercise of conversion of derivative security	$359,750 $14.39 p/Share	25,000 Added 7.35%	315,279 Common Shares
Jun 29 2022	SELL Open market or private sale	$1,546,750 $61.87 p/Share	25,000 Reduced 7.93%	290,279 Common Shares
Jun 29 2022	BUY Exercise of conversion of derivative security	$314,250 $12.57 p/Share	25,000 Added 7.35%	315,279 Common Shares
Mar 14 2022	SELL Payment of exercise price or tax liability	$253,665 $61.08 p/Share	4,153 Reduced 1.41%	290,279 Common Shares
Mar 11 2022	SELL Payment of exercise price or tax liability	$343,267 $62.56 p/Share	5,487 Reduced 1.89%	285,432 Common Shares
Mar 11 2022	BUY Exercise of conversion of derivative security	-	9,000 Added 2.97%	294,432 Common Shares
Mar 10 2022	BUY Exercise of conversion of derivative security	-	11,834 Added 3.91%	290,919 Common Shares
Dec 20 2021	BUY Exercise of conversion of derivative security	$32,127 $1.81 p/Share	17,750 Added 5.98%	279,085 Common Shares
Dec 06 2021	SELL Payment of exercise price or tax liability	$2,615,871 $69.17 p/Share	37,818 Reduced 12.64%	261,335 Common Shares
Dec 03 2021	BUY Exercise of conversion of derivative security	-	80,000 Added 21.1%	299,153 Common Shares
Dec 01 2021	SELL Payment of exercise price or tax liability	$58,503 $75.1 p/Share	779 Reduced 0.35%	219,153 Common Shares
Oct 15 2021	BUY Exercise of conversion of derivative security	$59,730 $1.81 p/Share	33,000 Added 13.05%	219,932 Common Shares
Sep 01 2021	SELL Payment of exercise price or tax liability	$98,241 $124.83 p/Share	787 Reduced 0.42%	186,932 Common Shares
Aug 05 2021	SELL Open market or private sale	$3,668,805 $128.73 p/Share	28,500 Reduced 13.18%	187,719 Common Stock
Aug 05 2021	BUY Exercise of conversion of derivative security	$358,245 $12.57 p/Share	28,500 Added 11.65%	216,219 Common Stock
Aug 04 2021	SELL Open market or private sale	$187,530 $125.02 p/Share	1,500 Reduced 0.79%	187,719 Common Shares
Aug 04 2021	BUY Exercise of conversion of derivative security	$18,855 $12.57 p/Share	1,500 Added 0.79%	189,219 Common Shares
Jun 15 2021	SELL Open market or private sale	$3,797,700 $126.59 p/Share	30,000 Reduced 13.78%	187,719 Common Shares
Jun 15 2021	BUY Exercise of conversion of derivative security	$377,100 $12.57 p/Share	30,000 Added 12.11%	217,719 Common Shares
Jun 01 2021	SELL Payment of exercise price or tax liability	$90,208 $115.8 p/Share	779 Reduced 0.41%	187,719 Common Shares
Mar 10 2021	SELL Payment of exercise price or tax liability	$686,053 $124.15 p/Share	5,526 Reduced 2.85%	188,498 Common Shares
Mar 10 2021	BUY Exercise of conversion of derivative security	-	11,833 Added 5.75%	194,024 Common Shares
Mar 01 2021	SELL Payment of exercise price or tax liability	$103,940 $130.25 p/Share	798 Reduced 0.44%	182,191 Common Shares
Jan 15 2021	SELL Open market or private sale	$4,289,800 $214.49 p/Share	20,000 Reduced 9.85%	182,989 Common Shares
Jan 15 2021	BUY Exercise of conversion of derivative security	$36,200 $1.81 p/Share	20,000 Added 8.97%	202,989 Common Shares

Also insider at

BDTX

Black Diamond Therapeutics, Inc. Healthcare

RPTX

Repare Therapeutics Inc. Healthcare

CNTA

Centessa Pharmaceuticals plc Healthcare

Director